Mirum Pharmaceuticals, Inc. MIRM Livmarli — Development or regulatory milestones incurred
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept mirm:DevelopmentOrRegulatoryMilestonesIncurred.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001759425-26-000045
which was recognized in acquired in-process research and development expense in the accompanying unaudited condensed consolidated statements of operations. In addition, as of December 31, 2025, the Company accrued $10.0 million for the achievement of a commercial milestone associated with product sales, which was recognized as an intangible asset. There were no volixibat development and regulatory milestones achieved during the three and six months ended June 30, 2026 and 2025.
Item 1. Financial Statements (Unaudited)
FAQ
- What is Mirum Pharmaceuticals, Inc.'s livmarli — development or regulatory milestones incurred?
- Mirum Pharmaceuticals, Inc. (MIRM) reported livmarli — development or regulatory milestones incurred of $0 in Q2 2026.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s livmarli — development or regulatory milestones incurred?
- Over 2 years (2021 to 2024), Mirum Pharmaceuticals, Inc.'s livmarli — development or regulatory milestones incurred has grown at a -100.0% compound annual growth rate (CAGR), from $32M to $0.
- What does livmarli — development or regulatory milestones incurred mean?
- Tracks the costs recognized when specific development or regulatory targets are reached for a product. This metric helps investors understand the timing and magnitude of expenses tied to the advancement of the drug pipeline.
Ask your AI about Mirum Pharmaceuticals, Inc.'s livmarli — development or regulatory milestones incurred.
Connect your AI assistant and compare it to peers, right in your chat.
